These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21227392)

  • 41. A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer.
    Ruan W; Chen X; Huang M; Wang H; Chen J; Liang Z; Zhang J; Yu Y; Chen S; Xu S; Hu T; Li X; Guo Y; Jiang Z; Chen Z; Huang J; Lin T; Fan JB
    Clin Epigenetics; 2021 Apr; 13(1):91. PubMed ID: 33902700
    [TBL] [Abstract][Full Text] [Related]  

  • 42. KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients.
    Cebrian V; Fierro M; Orenes-Piñero E; Grau L; Moya P; Ecke T; Alvarez M; Gil M; Algaba F; Bellmunt J; Cordon-Cardo C; Catto J; López-Beltrán A; Sánchez-Carbayo M
    Am J Pathol; 2011 Aug; 179(2):540-6. PubMed ID: 21683672
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.
    Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P
    Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A three-gene methylation marker panel for the nodal metastatic risk assessment of muscle-invasive bladder cancer.
    Stubendorff B; Wilhelm K; Posselt K; Catto J; Hartmann A; Bertz S; Füssel S; Novotny V; Toma M; Gajda M; Lehmann J; Wunderlich H; Grimm MO; Stöckle M; Junker K
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):811-820. PubMed ID: 30603903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events.
    Serizawa RR; Ralfkiaer U; Steven K; Lam GW; Schmiedel S; Schüz J; Hansen AB; Horn T; Guldberg P
    Int J Cancer; 2011 Jul; 129(1):78-87. PubMed ID: 20824703
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detecting DNA methylation of the BCL2, CDKN2A and NID2 genes in urine using a nested methylation specific polymerase chain reaction assay to predict bladder cancer.
    Scher MB; Elbaum MB; Mogilevkin Y; Hilbert DW; Mydlo JH; Sidi AA; Adelson ME; Mordechai E; Trama JP
    J Urol; 2012 Dec; 188(6):2101-7. PubMed ID: 23083854
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
    Gross E; van Tinteren H; Li Z; Raab S; Meul C; Avril S; Laddach N; Aubele M; Propping C; Gkazepis A; Schmitt M; Meindl A; Nederlof PM; Kiechle M; Lips EH
    BMC Cancer; 2016 Oct; 16(1):811. PubMed ID: 27756336
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
    Kandimalla R; van Tilborg AA; Kompier LC; Stumpel DJ; Stam RW; Bangma CH; Zwarthoff EC
    Eur Urol; 2012 Jun; 61(6):1245-56. PubMed ID: 22284968
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression.
    Vallot C; Stransky N; Bernard-Pierrot I; Hérault A; Zucman-Rossi J; Chapeaublanc E; Vordos D; Laplanche A; Benhamou S; Lebret T; Southgate J; Allory Y; Radvanyi F
    J Natl Cancer Inst; 2011 Jan; 103(1):47-60. PubMed ID: 21173382
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma.
    Yeh CM; Chen PC; Hsieh HY; Jou YC; Lin CT; Tsai MH; Huang WY; Wang YT; Lin RI; Chen SS; Tung CL; Wu SF; Chang DC; Shen CH; Hsu CD; Chan MW
    Oncotarget; 2015 Oct; 6(30):29555-72. PubMed ID: 26320192
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Methylcap-seq reveals novel DNA methylation markers for the diagnosis and recurrence prediction of bladder cancer in a Chinese population.
    Zhao Y; Guo S; Sun J; Huang Z; Zhu T; Zhang H; Gu J; He Y; Wang W; Ma K; Wang J; Yu J
    PLoS One; 2012; 7(4):e35175. PubMed ID: 22529986
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Methylation analysis of tumor suppressor genes in endometroid carcinoma of endometrium using MS-MLPA.
    Dvorakova E; Chmelarova M; Laco J; Palicka V; Spacek J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Dec; 157(4):298-303. PubMed ID: 23736679
    [TBL] [Abstract][Full Text] [Related]  

  • 53. p16INK4a and p14ARF methylation as a potential biomarker for human bladder cancer.
    Kawamoto K; Enokida H; Gotanda T; Kubo H; Nishiyama K; Kawahara M; Nakagawa M
    Biochem Biophys Res Commun; 2006 Jan; 339(3):790-6. PubMed ID: 16316628
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Three Protein-Coding Gene Prognostic Model Predicts Overall Survival in Bladder Cancer Patients.
    Ning XH; Qi YY; Wang FX; Li SC; Jia ZK; Yang JJ
    Biomed Res Int; 2020; 2020():7272960. PubMed ID: 33150179
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer.
    Kitchen MO; Bryan RT; Emes RD; Glossop JR; Luscombe C; Cheng KK; Zeegers MP; James ND; Devall AJ; Mein CA; Gommersall L; Fryer AA; Farrell WE
    Epigenetics; 2016 Mar; 11(3):237-46. PubMed ID: 26929985
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Correlation of LINE-1 methylation levels in patient-matched buffy coat, serum, buccal cell, and bladder tumor tissue DNA samples.
    van Bemmel D; Lenz P; Liao LM; Baris D; Sternberg LR; Warner A; Johnson A; Jones M; Kida M; Schwenn M; Schned AR; Silverman DT; Rothman N; Moore LE
    Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1143-8. PubMed ID: 22539607
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Urine cell-based DNA methylation classifier for monitoring bladder cancer.
    van der Heijden AG; Mengual L; Ingelmo-Torres M; Lozano JJ; van Rijt-van de Westerlo CCM; Baixauli M; Geavlete B; Moldoveanud C; Ene C; Dinney CP; Czerniak B; Schalken JA; Kiemeney LALM; Ribal MJ; Witjes JA; Alcaraz A
    Clin Epigenetics; 2018; 10():71. PubMed ID: 29854012
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multiplexed methylation profiles of tumor suppressor genes and clinical outcome in oligodendroglial tumors.
    Kuo LT; Lu HY; Lee CC; Tsai JC; Lai HS; Tseng HM; Kuo MF; Tu YK
    Cancer Med; 2016 Aug; 5(8):1830-9. PubMed ID: 27367901
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methylation analysis of tumour suppressor genes in ovarian cancer using MS-MLPA.
    Chmelařová M; Křepinská E; Spaček J; Laco J; Nekvindová J; Palička V
    Folia Biol (Praha); 2012; 58(6):246-50. PubMed ID: 23438850
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification and validation of methylated PENK gene for early detection of bladder cancer using urine DNA.
    Oh TJ; Lim E; Bang BR; Lee JJ; Na YG; Shin JH; Lim JS; Song KH; An S
    BMC Cancer; 2022 Nov; 22(1):1195. PubMed ID: 36403035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.